S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
S&P 500   3,768.25 (-0.72%)
DOW   30,814.26 (-0.57%)
QQQ   311.86 (-0.79%)
AAPL   127.14 (-1.37%)
MSFT   212.65 (-0.17%)
FB   251.36 (+2.33%)
GOOGL   1,727.62 (-0.19%)
AMZN   3,104.25 (-0.74%)
TSLA   826.16 (-2.23%)
NVDA   514.38 (-2.58%)
BABA   243.46 (+0.20%)
CGC   33.39 (-3.55%)
GE   11.33 (-2.83%)
MU   80.72 (-0.71%)
AMD   88.21 (-2.84%)
T   29.17 (-0.41%)
NIO   56.27 (-7.56%)
F   9.83 (-3.34%)
ACB   12.04 (+0.67%)
BA   204.32 (-2.66%)
DIS   171.44 (-1.15%)
NFLX   497.98 (-0.58%)
GILD   63.33 (+1.49%)
Log in
OTCMKTS:VGLS

VG Life Sciences Stock Forecast, Price & News

$0.0098
0.00 (-16.95 %)
(As of 01/15/2021 03:59 PM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01▼
$0.02
50-Day Range
$0.00
MA: $0.01▼
$0.02
52-Week Range
$0.00
Now: $0.01▼
$0.03
Volume22.03 million shs
Average Volume16.22 million shs
Market Capitalization$1.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1.67
VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.

MarketRank™

Overall MarketRank™

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:VGLS
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.vglifesciences.com
Phone805-879-9000
Employees1

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares129,928,000
Market Cap$1.27 million
Next Earnings DateN/A
OptionableNot Optionable
$0.0098
0.00 (-16.95 %)
(As of 01/15/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VGLS News and Ratings via Email

Sign-up to receive the latest news and ratings for VGLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











VG Life Sciences (OTCMKTS:VGLS) Frequently Asked Questions

What stocks does MarketBeat like better than VG Life Sciences?

Wall Street analysts have given VG Life Sciences a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but VG Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting VG Life Sciences?

VG Life Sciences saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 15,100 shares, an increase of 15,000.0% from the December 15th total of 100 shares. Based on an average daily trading volume, of 18,897,000 shares, the short-interest ratio is currently 0.0 days.
View VG Life Sciences' Short Interest.

Who are some of VG Life Sciences' key competitors?

Some companies that are related to VG Life Sciences include Nexien BioPharma (NXEN), iCo Therapeutics (ICOTF), Peak Pharmaceuticals (PKPH), AngioSoma (SOAN), Tower One Wireless (TOWTF), Helix BioMedix (HXBM), Acura Pharmaceuticals (ACUR), BriaCell Therapeutics (BCTXF), Wize Pharma (WIZP), International Stem Cell (ISCO), Innovus Pharmaceuticals (INNV), Benitec Biopharma (BNTC), Intellipharmaceutics International (IPCIF), Akorn (AKRXQ) and Amarantus BioScience (AMBS).
View all of VGLS's competitors.

Who are VG Life Sciences' key executives?

VG Life Sciences' management team includes the following people:
  • Mr. Haig Keledjian, Co-Founder, Chairman, CEO, Pres, VP of R&D, CFO and Sec. (Age 59)
  • Dr. M. Karen Newell-Rogers Ph.D., Chief Scientist
  • Robert A. Forrester, Corp. Counsel
  • Mr. Robert Berliner, Consultant & Advisory Board Member

What is VG Life Sciences' stock symbol?

VG Life Sciences trades on the OTCMKTS under the ticker symbol "VGLS."

How do I buy shares of VG Life Sciences?

Shares of VGLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is VG Life Sciences' stock price today?

One share of VGLS stock can currently be purchased for approximately $0.01.

How big of a company is VG Life Sciences?

VG Life Sciences has a market capitalization of $1.27 million. VG Life Sciences employs 1 workers across the globe.

What is VG Life Sciences' official website?

The official website for VG Life Sciences is www.vglifesciences.com.

How can I contact VG Life Sciences?

VG Life Sciences' mailing address is 121 GRAY AVENUE SUITE 200, SANTA BARBARA CA, 93101. The company can be reached via phone at 805-879-9000 or via email at [email protected]

This page was last updated on 1/15/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.